Regulation of neuronal cell death signalling for the treatment of neurodegenerative diseases. The progression of neurodegenerative diseases, such as Alzheimer's and motor neuron diseases, are often underpinned by neuronal cell death-signalling. This project aims to characterise molecules that regulate cell death signalling, thereby increasing our knowledge of how neuronal cell death can be inhibited.
New tools to activate and silence neural circuits. Many neurological disorders occur as a result of neuron cell death that is initiated by excessive levels of excitatory activity in central nervous system neurons. This project will develop and validate a new treatment for these disorders that involves silencing excessive neuronal activity using a safe, commonly prescribed drug.
The role of actin in driving bulk endocytosis in neurons and neurosecretory cells. Synaptic release of neurotransmitter is essential for neuronal communication. Following fusion, synaptic vesicle membrane is incorporated into the plasma membrane and retrieved by endocytosis to recover both lipids and essential vesicular proteins. The project will characterise how the actin cytoskeleton perform this function.
Engineering layered double hydroxide nanoparticles toward an efficient targeted clinical delivery system. This project will develop a more effective drug delivery system using clay nanoparticles and biofriendly serum proteins. Outcomes from this project will provide a tremendous opportunity for potent therapies of cancers, vasculature and neuronal diseases, and place Australia at the forefront of nanotechnology drug delivery research.
Development of novel reagents that specifically counteract EphA4 to enhance axonal regeneration. This project will examine the role of EphA4, an important guidance protein, in neural cell regeneration. The goal is to understand the signalling mechanisms that inhibit regeneration in the central nervous system and to develop novel biological agents to overcome these processes and promote functional recovery after nervous system injury or disease.
Molecules and mechanisms regulating axonal degeneration and regeneration in Caenorhabditis elegans neurons. Understanding the molecular mechanisms underlying nerve degeneration and regeneration is essential to tackle and provide treatment for neurodegenerative diseases and injury of the nervous system. This project aims to discover, using a genetic approach and a simple animal model system, the molecules regulating these crucial biological processes.
The role of synapse development in cognitive disorder. In humans, intellectual disability occurs when nerve cells in the brain fail to connect. The project examines fundamental molecular processes involved in synapse development of neurons. The use of insect models provides a generalised biological template to understand how synaptic molecules contribute to behaviours that underlie cognitive disorder.
A VAST potential for ion channel drug discovery. The purpose of this project is to bring innovation into the methods used for identifying and characterising novel carbohydrate-based compounds acting at ion channels. These molecules will have high potential to be developed as highly effective treatments for pain without the unpleasant side-effects associated with current treatments.
Efficacy profiling innovation in novel pain therapeutics discovery. The purpose of this project is to bring innovation into the methods used for selecting novel compounds with high potential for progression into development as highly effective pain-killers for improving the relief of chronic pain. This will result in new pain-killers that are highly effective without producing unpleasant side-effects.
Revealing how the human brain coordinates body movements for applications in health and technology. This project will extend the basic understanding about how the brain controls the movements of our bodies, and how it changes to allow us to adapt and refine our movements. This project will generate information that is critical for applications in the fields of health (e.g. rehabilitation) and technology (e.g. human-machine interfaces).